KIMS Reports Q1 FY27 Results: Revenue Up 35.3% YoY to ₹11,795 Million, EBITDA Rises 20.1%
KIMS reported Q1 FY27 operating revenue of ₹11,795 million (₹1,179.5 crore), up 35.3% YoY. EBITDA rose 20.1% to ₹2,398 million (₹239.8 crore). IP volume increased by 26.6% and OP volume by 8.0%. ARPOB grew 9.7% to ₹47,200. The company added 787 beds in Kondapur and 208 in Palakkad.
The announcement details significant financial performance metrics (revenue and EBITDA growth) and operational highlights (volume growth, bed capacity expansion), which are material for investors and stakeholders.
The company reported strong year-on-year growth in operating revenue and EBITDA, indicating positive business performance. While PBT and PAT saw a decline, this was attributed to specific statutory impacts and fair valuation adjustments, with operational metrics showing a positive trend.
Krishna Institute of Medical Sciences Limited (KIMS) has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a significant year-on-year growth in its top line, with operating revenue increasing by 35.3% to ₹11,795 million (₹1,179.5 crore) compared to ₹8,716 million (₹871.6 crore) in Q1 FY26.
EBITDA for the quarter stood at ₹2,398 million (₹239.8 crore), a 20.1% increase from ₹1,997 million (₹199.7 crore) in the same period last year. The EBITDA margin was reported at 20.1% for Q1 FY27, compared to 22.7% in Q1 FY26. Profit Before Tax (PBT) stood at ₹566 million (₹56.6 crore), a decrease of 50.2% from ₹1,137 million (₹113.7 crore) in Q1 FY26. Profit After Tax (PAT) was ₹374 million (₹37.4 crore), down 56.0% from ₹850 million (₹85.0 crore) in Q1 FY26.
Operationally, KIMS saw a 26.6% increase in In-Patient (IP) volume to 72,493 and an 8.0% increase in Out-Patient (OP) volume to 6,58,617. The Average Revenue Per Operating Bed (ARPOB) increased by 9.7% to ₹47,200, while Average Revenue Per Patient (ARPP) saw a modest increase of 6.8% to ₹1,63,573.
The company also highlighted key achievements in Q1 FY27, including the addition of 787 beds in Kondapur and 208 beds in Palakkad, expanding its total bed capacity. The presentation also detailed the ramp-up of operations in its Kerala, Maharashtra, Andhra Pradesh, and Karnataka units, along with O&M units, showcasing significant revenue and EBITDA growth in these regions.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.